Can Gilead Make Money From Its COVID-19 Treatment Remdesivir?

In this Fool Live video, healthcare and cannabis bureau chief Corinne Cardina and longtime Motley Fool contributor Brian Orelli discuss remdesivir, the antiviral from Gilead Sciences (NASDAQ: GILD), which is one of the treatments President Donald Trump received. The big biotech donated its initial stock of the drug, leading many investors to ponder whether Gilead can make any money from it. They also discuss the potential for combination treatments, which would lessen the possible impact of competition from other classes of drugs, such as monoclonal antibodies.

Continue reading

Source Fool.com